How Antimicrobial Peptides Drive Inflammation in Psoriasis | Research

The takeaway

Antimicrobial peptides like LL-37, defensins, and S100 proteins amplify psoriatic inflammation by enhancing immune recognition of self-DNA and self-RNA.

Self-DNA recognition
AMPs enhance binding of self-DNA and self-RNA to immune receptors, triggering the interferon cascade driving psoriasis

What the researchers found

AMPs amplify psoriatic inflammation by enhancing recognition of self-DNA/RNA as damage-associated molecular patterns, triggering interferon production from dendritic cells and keratinocytes.

Why it matters

Understanding how normally protective antimicrobial peptides paradoxically drive autoimmune skin inflammation could lead to targeted psoriasis therapies.

The numbers in context

3 AMP families (LL-37, β-defensin, S100); enhance DAMP recognition; drive Th17/Th1; NETs contain LL-37

How the study worked

Narrative review of published literature on AMP roles in psoriasis pathogenesis, including LL-37, defensins, S100, and their interactions with immune cells.

Who was studied

Review article (no study population)

What this study cannot tell us

Review article without new experimental data. Exact therapeutic targeting of AMP-mediated pathways in psoriasis remains to be developed.

How to read the evidence

Review article synthesizing mechanistic research. Strong explanatory framework but no new data.

When this study was published

Published in 2020. AMP roles in autoimmune skin disease continue to be investigated.

The bigger picture

This work reveals how the innate immune system's antimicrobial defenses can turn against the body in psoriasis, providing a mechanistic basis for the Köbner phenomenon (new lesions appearing at sites of skin injury).

Questions still open

Could blocking LL-37's interaction with self-DNA reduce psoriatic inflammation?
Are AMP-targeted therapies feasible without compromising antimicrobial defense?
Do AMP levels predict psoriasis severity or treatment response?

Common questions

How do antimicrobial peptides cause psoriasis?

AMPs like LL-37, normally produced to fight infection, can bind to self-DNA and self-RNA released from damaged skin cells. This complex activates immune receptors, triggering inflammatory cascades that drive the formation and maintenance of psoriatic lesions.

What is the Köbner phenomenon?

It's the appearance of new psoriasis lesions at sites of skin injury like scratches or cuts. This review explains it may occur because skin damage releases self-DNA that AMPs then bind to, triggering the inflammatory cascade that creates new psoriatic plaques.

Read the original research

Psoriasis and Antimicrobial Peptides.

International journal of molecular sciences, 21(18)

View on PubMed ↗Publisher’s paper ↗

Citation

Takahashi, Toshiya; Yamasaki, Kenshi. (2020). Psoriasis and Antimicrobial Peptides.. International journal of molecular sciences, 21(18). https://doi.org/10.3390/ijms21186791